Warning ! The cookie feature is disabled in your browser. Some features may not work properly.
Click here to learn how to activate your cookies. |
|
12th Congress of the European Hematology Association
|
|
|
|
Assoc. Prof. F. Cervantes
|
| Search Tips: here are some examples |
| Abdominal obesity | Returns slides that contain AT LEAST ONE of the words |
| +Abdominal +obesity | Returns slides with BOTH words |
| +Abdominal -obesity | Returns slides with Abdominal ONLY and eliminates all slides with obesity |
| Cardio* | Returns slides with Cardio, Cardiology, Cardiovascular, etc. |
| "Abdominal obesity" | Returns only slides with this EXACT COMBINATION and order of words |
|
|
|
|
|
Barcelona, Spain 
Hospital Clinic
Francisco Cervantes works as a senior consultant at the Hematology Department of the Hospital Clínic, in Barcelona, Spain, and is associate professor at the University of Barcelona. His scientific interest has been focused on the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative disorders (MPDs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published 167 articles in peer-review international journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology, Experimental Hematology, Haematologica, Cancer, Oncogene, Seminars in Oncology, and the European Journal of Haematology. In the field of CML, Dr. Cervantes contributed to the ellaboration of Sokal’s score, used worldwide for the prognostic stratification of CML patients, is a coauthor of the publications of the IRIS study, which allowed to establish imatinib as first-line treatment for CML and has participated in the introduction of the second-generation tyrosine kinase inhibitors for patients resistant to imatinib. In the MPDs field, Francisco Cervantes’ main contribution has been the ellaboration of a prognostic classification for younger patients with myelofibrosis, currently used to select those who are tributary of allogeneic hemopoietic stem cell transplant upfront, and he has also contributed to establish the role of leukocyte and platelet activation in the thrombosis of MPD patients. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for Myelofibrosis Research and Treatment, the European Leukemianet, and the Spanish Society of Hematology.
|
|
| Presentations by Assoc. Prof. F. Cervantes currently available on MultiWebcast.com |
12th Congress of the European Hematology Association
 |
Conventional and new treatment modalities in myelofibrosis
2007-06-08 - English - Myeloproliferative disorders
|
|
Conventional therapy of myelofibrosis is essentially palliative. It includes a wait-and-see approach for asymptomatic patients, oral cytolytic drugs such as hydroxyurea for the hyperproliferative forms of the disease, androgens or erythropoietin for the anemia, and...(more) |
|
|
|
|
|
|
|
